Almirall S.A.
- BID
10.9
- ASK
10.92
- 4,248 Units2,413 Units
- 07/21, 17:18:00 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
2.45%
Market Cap
1.57 Bil.
P/E Ratio
59.53
Dividend Yield
1.18 %
Earnings per Share
0.22 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 10.86 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 05:03:38 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 10.96 | 10.74 |
| PREV. DAY'S PRICE | 10.86 | (07/20) |
| CHANGE DAY BEFORE | +0.00 | 0.00 % |
| 52 WEEK HIGH / LOW | 13.94 (02/19) | 9.95 (08/07) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.20 | 0.05 | 0.22 | 0.39 | 0.56 |
DIVIDENDS PER SHARE | 0.15 | 0.15 | 0.15 | 0.20 | 0.21 |
DIVIDEND YIELD IN % | 1.77 % | 1.81 % | 1.18 % | - | - |
DIVIDEND GROWTH IN % | 0.00 % | 0.00 % | 1.63 % | - | - |
PRICE - EARNINGS RATIO | - | 171.56 | 59.53 | 28.42 | 19.71 |
PRICE - BOOK RATIO | 1.21 | 1.18 | 1.85 | - | - |
PRICE - SALES RATIO | 1.86 | 1.77 | 2.48 | - | - |
PRICE - CASH FLOW RATIO | 18.78 | 11.09 | 16.24 | - | - |
Master Data
| WKN | A0MU8Y |
| ISIN | ES0157097017 |
| SYMBOL | E2Z |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Almirall |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | 1.57 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 0.37 % | -1.99 % | -14.89 % | -10.84 % | 2.45 % | 32.93 % | -26.47 % | -16.20 % |
| HIGH | 10.92 | 11.76 | 12.96 | 13.94 | 13.94 | 13.94 | 15.17 | 13.94 |
| LOW | 10.46 | 10.46 | 10.46 | 10.46 | 9.95 | 7.64 | 7.11 | 10.46 |
Dividende
pro Aktie
Company profile
Almirall SA is a global biopharmaceutical company, which is focused on skin health. It engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The firm operates through the following segments: Marketing through Own Network(Europe), Marketing through Own Network(United States), Marketing by Licensees, Research and Development Activity, and Corporate and Manufacturing services segments. The company was founded in 1943 and is headquartered in Barcelona, Spain.
Structured products for Almirall S.A.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.